Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Therapeutic T cell engineering.

Sadelain M, Rivière I, Riddell S.

Nature. 2017 May 24;545(7655):423-431. doi: 10.1038/nature22395. Review.

2.

Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology.

Ebert LM, Yu W, Gargett T, Brown MP.

Biochem Soc Trans. 2018 Apr 17;46(2):391-401. doi: 10.1042/BST20170178. Epub 2018 Mar 14. Review.

PMID:
29540509
3.

Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy.

Mock U, Nickolay L, Philip B, Cheung GW, Zhan H, Johnston IC, Kaiser AD, Peggs K, Pule M, Thrasher AJ, Qasim W.

Cytotherapy. 2016 Aug;18(8):1002-11. doi: 10.1016/j.jcyt.2016.05.009.

PMID:
27378344
4.

The Principles of Engineering Immune Cells to Treat Cancer.

Lim WA, June CH.

Cell. 2017 Feb 9;168(4):724-740. doi: 10.1016/j.cell.2017.01.016. Review.

5.

FLAG-tagged CD19-specific CAR-T cells eliminate CD19-bearing solid tumor cells in vitro and in vivo.

Berahovich R, Xu S, Zhou H, Harto H, Xu Q, Garcia A, Liu F, Golubovskaya VM, Wu L.

Front Biosci (Landmark Ed). 2017 Jun 1;22:1644-1654.

PMID:
28410137
6.

Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.

Li S, Siriwon N, Zhang X, Yang S, Jin T, He F, Kim YJ, Mac J, Lu Z, Wang S, Han X, Wang P.

Clin Cancer Res. 2017 Nov 15;23(22):6982-6992. doi: 10.1158/1078-0432.CCR-17-0867. Epub 2017 Sep 14.

7.

Chimeric antigen receptor T-cell therapies for multiple myeloma.

Mikkilineni L, Kochenderfer JN.

Blood. 2017 Dec 14;130(24):2594-2602. doi: 10.1182/blood-2017-06-793869. Epub 2017 Sep 19. Review.

8.

Engineered T cells: the promise and challenges of cancer immunotherapy.

Fesnak AD, June CH, Levine BL.

Nat Rev Cancer. 2016 Aug 23;16(9):566-81. doi: 10.1038/nrc.2016.97. Review.

9.

IMMUNOLOGY. Fighting autoimmunity with immune cells.

Leslie M.

Science. 2016 Jul 1;353(6294):14. doi: 10.1126/science.353.6294.14. No abstract available.

PMID:
27365430
10.

Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.

Di S, Li Z.

Sci China Life Sci. 2016 Apr;59(4):360-9. doi: 10.1007/s11427-016-5025-6. Epub 2016 Mar 11. Review.

PMID:
26968709
11.

Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer.

Li F, Zhang T, Cao L, Zhang Y.

Curr Stem Cell Res Ther. 2018;13(5):327-335. doi: 10.2174/1574888X13666180420110239. Review.

PMID:
29676233
12.

CART trials are going ahead.

Wei J, Han W.

Sci China Life Sci. 2017 Nov;60(11):1276-1279. doi: 10.1007/s11427-017-9198-1. Epub 2017 Oct 26. No abstract available.

PMID:
29170890
13.

The promise and potential pitfalls of chimeric antigen receptors.

Sadelain M, Brentjens R, Rivière I.

Curr Opin Immunol. 2009 Apr;21(2):215-23. doi: 10.1016/j.coi.2009.02.009. Epub 2009 Mar 25. Review.

14.

CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road.

Gill S, Porter DL.

Expert Opin Biol Ther. 2014 Jan;14(1):37-49. doi: 10.1517/14712598.2014.860442. Epub 2013 Nov 21. Review.

PMID:
24261468
15.

T cell engineering as therapy for cancer and HIV: our synthetic future.

June CH, Levine BL.

Philos Trans R Soc Lond B Biol Sci. 2015 Oct 19;370(1680):20140374. doi: 10.1098/rstb.2014.0374. Review.

16.

Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective.

Rivière I, Sadelain M.

Mol Ther. 2017 May 3;25(5):1117-1124. doi: 10.1016/j.ymthe.2017.03.034. Epub 2017 Apr 26. Review.

17.

Designing chimeric antigen receptors to effectively and safely target tumors.

Jensen MC, Riddell SR.

Curr Opin Immunol. 2015 Apr;33:9-15. doi: 10.1016/j.coi.2015.01.002. Epub 2015 Jan 23. Review.

18.

Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.

Aldoss I, Bargou RC, Nagorsen D, Friberg GR, Baeuerle PA, Forman SJ.

Leukemia. 2017 Apr;31(4):777-787. doi: 10.1038/leu.2016.391. Epub 2016 Dec 28. Review.

PMID:
28028314
19.

Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.

Zhang BL, Qin DY, Mo ZM, Li Y, Wei W, Wang YS, Wang W, Wei YQ.

Sci China Life Sci. 2016 Apr;59(4):340-8. doi: 10.1007/s11427-016-5027-4. Epub 2016 Mar 11. Review.

PMID:
26965525
20.

T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.

Zah E, Lin MY, Silva-Benedict A, Jensen MC, Chen YY.

Cancer Immunol Res. 2016 Jun;4(6):498-508. doi: 10.1158/2326-6066.CIR-15-0231. Epub 2016 Apr 8.

Supplemental Content

Support Center